Semaphorin 7a Induced Lung Fibrogenesis Occurs in a CD-4-Dependent, Macrophage Dependent Manner
AssigneeYale University
InventorErica Herzog
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treating a mammal diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the mammal a compound or composition which modulates a target, such as Cofilin-1 and/or Plexin C1. The method of the invention also comprises administering to the mammal a compound or composition which inhibits a lymphocyte that expresses Sema 7a.
Claims27
A method of inhibiting fibrosis in a mammal at risk of developing fibrosis, said method comprising administering a therapeutically effective amount of a modulator of a target to said mammal, wherein the target is selected from the group consisting of Cofilin-1 (CFL-1), Plexin C1, and any combination thereof, thereby inhibiting fibrosis in said mammal.
A method of inhibiting fibrosis in a mammal diagnosed with a disease or disorder involving fibrosis, said method comprising administering a therapeutically effective amount of a modulator of a target to said mammal, wherein the target is selected from the group consisting of Cofilin-1 (CFL-1), Plexin C1, and any combination thereof, thereby inhibiting fibrosis in said mammal.
A method of inhibiting fibrosis in a mammal at risk of developing fibrosis, said method comprising administering a therapeutically effective amount of an inhibitor for a lymphocyte expressing Sema 7a to said mammal, thereby inhibiting fibrosis in said mammal.
Dependencies are inferred from the claim text.